D. Boral Capital Reiterates “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $31.00 price target on the stock.

Several other equities research analysts also recently commented on NRXP. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price on shares of NRx Pharmaceuticals in a research note on Monday, November 25th. Ascendiant Capital Markets boosted their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Finally, EF Hutton Acquisition Co. I raised NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st.

NRx Pharmaceuticals Trading Up 43.8 %

NRx Pharmaceuticals stock opened at $2.20 on Tuesday. The firm has a market capitalization of $26.61 million, a P/E ratio of -1.03 and a beta of 1.25. The business has a 50-day moving average of $1.33 and a 200-day moving average of $1.76. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $7.33.

Insider Buying and Selling at NRx Pharmaceuticals

In other news, Chairman Jonathan C. Javitt acquired 40,000 shares of NRx Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The stock was bought at an average cost of $1.17 per share, with a total value of $46,800.00. Following the completion of the transaction, the chairman now directly owns 84,634 shares of the company’s stock, valued at approximately $99,021.78. This represents a 89.62 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 19.00% of the company’s stock.

Institutional Investors Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP purchased a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned approximately 1.33% of NRx Pharmaceuticals as of its most recent SEC filing. 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.